Tuesday evening's Ambu downgrade is obviously not good news, having made waves in the share price on Wednesday, but the medtech company's announcement really doesn't change its investment case, at least according to Senior Equity Analyst at Sydbank Søren Løntoft Hansen.
"On the face of things it seems to be discouraging news from Ambu. Having said that, Ambu is priced on the expectations for its visualization business, and this isn't where the company has been affected by shipment delays," Løntoft Hansen says, highlighting, however, that the challenges in shipping, which cost the company DKK 75m (USD 11.7m) in the fourth quarter, will bleed into the next financial year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
WS Audiology brings in head of EMEA region from Coloplast
The hearing aid manufacturer has appointed Coloplast’s now outgoing president for emerging markets as president for the EMEA region.
Dupixent could dominate pediatric eczema market for up to a decade, analysis finds
Sanofi and Regeneron will be able to call themselves market leaders within atopic eczema treatment for children aged 6 months to 5 for years to come, according to Globaldata.
FDA advisors support approval for Ferring's intestinal infection medicine
All signs indicate that Ferring Pharmaceuticals is on the cusp of being market authorized for its biologic candidate against C. difficile infection.
Pharmacosmos expects massive growth in four years
The company’s new chief executive has ambitions of reaching a DKK 2.5bn (USD 325m) revenue within the time frame.
The Lundbeck Foundation, ATP, LEGO asset manager join forces on secretive project
Three of Denmark’s biggest funds have come together for a yet unknown project, which includes the establishment of three new firms.
Senior Clinical Research Scientist 
Manager for Process Support - 1st line support 
Experienced IT Business Solutions Manager for the Danish Medicines Agency 
Product specialist 
Sales Manager Denmark 
Pharmacovigilance & Regulatory Officer 
Clinical Project Lead 
Lab Manager 
Product specialist in Cardio Rhythm Management, Zealand 
Pharmacovigliance (Associate) Director or Senior Specialist 
Senior/lead consultant at Emendo Engineering 
Scientist Radiochemistry